Phosphoinositide 3-kinase

Mayor Johnson Proclaims International Brain Tumor Awareness Week, Local Researchers Pave the Way to a Treatment

Retrieved on: 
Friday, October 29, 2021
Death, PI3K, Brain, Research, City, UCSD, Cancer, Disease, Neoplasm, Awareness, Phosphoinositide 3-kinase, Glioblastoma, Patient, SEC, Traffic barrier, GCT, Time, Technology, CEO, COVID-19, Therapy, Barrow Neurological Institute, Pneumonia, Medical imaging

Local researchers from Global Cancer Technology are currently executing on promising pre-clinical studies that could provide a new treatment for glioblastomaan aggressive form of brain cancerand a pathway to an eventual cure.

Key Points: 
  • Local researchers from Global Cancer Technology are currently executing on promising pre-clinical studies that could provide a new treatment for glioblastomaan aggressive form of brain cancerand a pathway to an eventual cure.
  • Glioblastoma is the most common malignant brain tumor, representing 48.6-percent of all malignant brain tumors .
  • Brain tumors impact thousands of Texans each year, including former United States Representative Frank Tejeda, who died of pneumonia after a yearlong battle with brain cancer in1997.
  • Clark added, "It is only a matter of time before the brain cancer community finds a way to treat glioblastoma and other forms of aggressive brain cancer.

SynDevRx Announces Research Collaboration with Maine Medical Center Research Institute to Study the Effects of SDX-7320 In Obesity-Accelerated Multiple Myeloma Models

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Medical specialties, Medicine, Oncology, Multiple myeloma, Metástasis, Bone marrow, Cancer

The collaboration will study the role of MetAP2 in obesity-accelerated growth and metastatic potential of multiple myeloma a form of cancer that develops in bone marrow.

Key Points: 
  • The collaboration will study the role of MetAP2 in obesity-accelerated growth and metastatic potential of multiple myeloma a form of cancer that develops in bone marrow.
  • "We're excited to test this drug, SDX-7320, in these models of cancers accelerated by obesity," lead investigator Michaela Reagan, PhD, said.
  • "Obesity changes the composition of the blood and bone marrow, making it more conducive for multiple myeloma cells to develop or proliferate.
  • "Maine Medical Center, and Dr. Reagan in particular, have some of the best models for illustrating the effects obesity has on the microenvironment of multiple myeloma," noted SynDevRx Sr. Director of Translational Research, Dr. Peter Cornelius, PhD.

Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU

Retrieved on: 
Monday, June 21, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials, Branches of biology, Biology, Oncology, Cell signaling, Programmed cell death, Phosphoinositide 3-kinase, Signal transduction, Kinase, Apoptosis, Phosphoinositide 3-kinase inhibitor, PI3K/AKT/mTOR pathway, Aliqopa® (copanlisib) Injection, non-Hodgkin’s Lymphoma, Oncology at Bayer, Bayer, ALIQOPA® (COPANLISIB) INJECTION, NON-HODGKIN’S LYMPHOMA, ONCOLOGY AT BAYER, BAYER

In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.

Key Points: 
  • In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.
  • Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K- and PI3K- isoforms expressed in malignant B cells.
  • Aliqopa has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.
  • The clinical development program for Aliqopa also includes the Phase III study CHRONOS-4, evaluating Aliqopa in combination with standard immunochemotherapy in relapsed iNHL.

Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma

Retrieved on: 
Tuesday, June 15, 2021
Health, Oncology, Medicine, Metabolism, Brain tumor, Drug discovery, Cancer, Glioblastoma, Ketosis, Phosphoinositide 3-kinase, Ketogenic diet, Clinical trial

Our research clearly shows the synergistic benefits of PI3K inhibition and ketosis in animal models of glioblastoma.

Key Points: 
  • Our research clearly shows the synergistic benefits of PI3K inhibition and ketosis in animal models of glioblastoma.
  • For these reasons, there is a sound rationale to explore a combination of ketogenic diet and paxalisib in glioblastoma.
  • The diet will be overseen by expert clinical dieticians to ensure that it is scientifically appropriate and that patients are compliant.
  • The initiation of this trial in glioblastoma brings the number of ongoing clinical studies of paxalisib in brain cancer to nine.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

Retrieved on: 
Friday, June 11, 2021
Protein kinases, Signal transduction, Ck1, Casein kinase 1, Phosphoinositide 3-kinase, Kinase, PI3

Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress.

Key Points: 
  • Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress.
  • UKONIQ is a registered trademark of TG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.
  • CK1-epsilonis a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies.
  • Monitor for any new or worsening signs and symptoms of infection, including suspected PJP or CMV, during treatment with UKONIQ.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Protein kinases, Signal transduction, Casein kinase 1, Phosphoinositide 3-kinase, Ck1, PI3

Data from this trial were made available on demand this morning during the American Societyof Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Data from this trial were made available on demand this morning during the American Societyof Clinical Oncology (ASCO) Annual Meeting.
  • TG-1701 monotherapy was well tolerated and the maximum tolerated dose was not reached up to 400 mg QD.
  • TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • UKONIQ is a registered trademark of TG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.

Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Branches of biology, Signal transduction, Clinical medicine, Medicine, Oncology, Drug discovery, Phosphoinositide 3-kinase inhibitor, Phosphoinositide 3-kinase, MTOR, Antineoplastic drugs, Quinolines, Dactolisib

Globally, there are no PI3K inhibitors that have been approved for the treatment of T cell lymphomas.

Key Points: 
  • Globally, there are no PI3K inhibitors that have been approved for the treatment of T cell lymphomas.
  • Another clinical study of linperlisib was also presented at ASCO entitled "A phase Ib study of the PI3K inhibitor linperlisib in patients with advanced solid tumors".
  • "YL-13027 has demonstrated to be a safe and tolerable oral agent that is highly selective for TGFR1 over TGFR2.
  • Yingli Pharma is developing best-in-class and first-in-class oral investigational agents for the treatment of cancer, metabolic and autoimmune diseases.

Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Signal transduction, Biology, Oncology, PI3K/AKT/mTOR pathway, Protein kinases, Phosphoinositide 3-kinase, Protein kinase B, MTOR, Diffusion Pharmaceuticals

The study evaluated the safety and tolerability of TSC when administered every six hours for up to 15 days, a dosing regimen previously untested in a clinical trial setting.

Key Points: 
  • The study evaluated the safety and tolerability of TSC when administered every six hours for up to 15 days, a dosing regimen previously untested in a clinical trial setting.
  • Topline results, reported in mid-February 2021, showed that all doses evaluated were well tolerated and no dose-limiting toxicities or serious adverse events were observed.
  • Diffusion intends to initiate clinical studies in the identified indications during the first quarter of 2022.\nDiffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body\xe2\x80\x99s ability to deliver oxygen to areas where it is needed most.
  • In addition to TSC, Diffusion\xe2\x80\x99s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Signal transduction, Medical specialties, Hematology, Protein kinases, Oncology, PI3K/AKT/mTOR pathway, MTOR, Thrombosis, Protein kinase B, Phosphoinositide 3-kinase, Venous thrombosis

In addition, no patients required dialysis or developed acute kidney injury and there were no reports of pulmonary embolism or deep vein thrombosis.

Key Points: 
  • In addition, no patients required dialysis or developed acute kidney injury and there were no reports of pulmonary embolism or deep vein thrombosis.
  • The medical and scientific communities have since come to understand COVID-19 is a much more complex disease, and the study itself was complicated to conduct.
  • The primary endpoint evaluates the relative change in TCOM readings from baseline after TSC administration.
  • In addition to TSC, Diffusion\xe2\x80\x99s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Thursday, March 4, 2021
Branches of biology, Signal transduction, Biology, Protein kinases, Oncology, PI3K/AKT/mTOR pathway, MTOR, Protein kinase B, Phosphoinositide 3-kinase, Diffusion Pharmaceuticals, Phosphoinositide 3-kinase inhibitor, mTOR inhibitors

Duringthepresentation, Dr. Cobuzzi willprovide an overview ofDiffusions recent corporate achievements, planned clinical trials, as well as potential milestones.

Key Points: 
  • Duringthepresentation, Dr. Cobuzzi willprovide an overview ofDiffusions recent corporate achievements, planned clinical trials, as well as potential milestones.
  • Our presentation will be available here , on the Investor Relations section of our website following the conference.
  • Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most.
  • In addition to TSC, Diffusions product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.